ASIANET: INTL ORGANON ENGLISH UNIVERSAL NEWS SERVICES

ข่าวต่างประเทศ Wednesday August 6, 1997 09:50 —Asianet Press Release

INTL ORGANON ENGLISH UNIVERSAL NEWS SERVICES - INTERNATIONAL BUSINESS NEWS SERVICE LIVIAL PROTECTIVE IN ATHEROSCLEROSIS STUDIES SHOW TISSUE-SPECIFIC EFFECT AFTER MENOPAUSE PRESS INFORMATION FROM FIGO '97 XV WORLD CONGRESS OF GYNAECOLOGY AND OBSTETRICS Copenhagen/Oss, August 5, 1997 -/TWO-TEN/AsiaNet/ Livial, the world's first hormonal monotherapy designed to remove the need for regular bleeding after the menopause, has been shown in laboratory studies to be more powerful than estrogens in the prevention of atherosclerosis, the process by which cholestrol deposits in arteries cause coronary heart disease. The findings emerged from a study presented by Dr Pieter Zandberg, of the Department of Vascular Pharmacology at NV Organon, the Netherlands, the developers of Livial. He described a study in a well established animal model of atherosclerosis in which Livial almost completely prevented cholesterol accumulation in the vessel wall and the formation of plaques. Estradiol, a natural estrogen, showed only intermediary effects on these markers of coronary heart disease. The results presented yesterday reflect the broad 'tissue-specific' effects which Livial is now known to produce a positive estrogenic effect on menopausal symptoms, osteoporosis, vaginal tisue and mood, without estrogenic stimulation of the endometrium. Preliminary studies - to be reported later this week - also demonstrate no estrogenic effects on breast tissue. It is for such reasons researchers such as New York osteoporosis expert Professor Robert Lindsay have described Livial as the 'mother compound' for a whole new tissue-specific approach in postmenopausal hormones pioneered by Organon. Other compounds aiming to achieve a similar approach include 'selective estrogen receptor modulators', or SERMs, such as raloxifene. Because this new class of hormone treatment has a selective effect on specific target sites, experts here at this congress predict trend-setting compounds, such as Livial, are now pointing the way forward in postmenopausal HRT - to increase beneficial effects at desired target sites (bone or cardiovascular system) and lower the risk of unwanted stimulation at other sites (breast or endometrium). Said Dr. Willem de Laat, Medical Director of NV Organon in The Netherlands: "The challenge in postmenopausal hormone therapy is to stimulate some tissues - such as bone or the cardiovascular system -but not stimulate the endometrium and breast. Against a background of uncertainty in conventional HRT, we are sure that tissue-specific products like Livial will lead postmenopausal therapies into a new era." Livial is in its world-wide introduction programme and currently available in more than 30 countries. NV Organon develops and produces pharmaceutical products in fields such as gynaecology, psychiatry, thrombosis, and auto-immune diseases. Major product groups are oral contraceptives, infertility treatments and preparations for menopausal complaints, depression, and psychosis. NV Organon is one of the pharmaceutical business units of Azko Nobel. Background details of Livial are available on request. UNS Contact: Mrs. H. van Leeuwe-Bak, NV Organon, Oss, the Netherlands, Tel: +31 412 662947, Fax: +31 412 662568 or Dr B. Oddens, NV Organon at FIGO, Copenhagen, Courtesy room: tel: +45 32 472863, E-mail: [email protected] Internet: http://www.ics.dk/figo97

แท็ก nation   asian   ESSO   auto   ICT  

เว็บไซต์นี้มีการใช้งานคุกกี้ ศึกษารายละเอียดเพิ่มเติมได้ที่ นโยบายความเป็นส่วนตัว และ ข้อตกลงการใช้บริการ รับทราบ